These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 28760556)

  • 21. Exponential rise in prostate-specific antigen (PSA) during anti-androgen withdrawal predicts PSA flare after docetaxel chemotherapy in patients with castration-resistant prostate cancer.
    Han KS; Hong SJ
    Yonsei Med J; 2015 Mar; 56(2):368-74. PubMed ID: 25683983
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Fosbøl MØ; Petersen PM; Kjaer A; Mortensen J
    J Nucl Med; 2018 Apr; 59(4):596-602. PubMed ID: 28864632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Predictive value of prostate-specific antigen and Gleason sum for results of radionuclide bone scintigraphy in patients with prostate cancer].
    Wang TY; Chen XP; Li XS; Jia Yx; Cheng J; Zhang JH; Cai L; Zhang Z; Gong K; He ZS; Zhou LQ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Aug; 44(4):528-34. PubMed ID: 22898839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapidly decreasing level of prostate-specific antigen during initial androgen deprivation therapy is a risk factor for early progression to castration-resistant prostate cancer: A retrospective study.
    Ji G; Song G; Huang C; He S; Zhou L
    Medicine (Baltimore); 2017 Sep; 96(36):e7823. PubMed ID: 28885333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone scan index (BSI) scoring by using bone scintigraphy and circulating tumor cells (CTCs): predictive factors for enzalutamide effectiveness in patients with castration-resistant prostate cancer and bone metastases.
    Hirano H; Nagata M; Nagaya N; Nakamura S; Ashizawa T; Lu Y; Kawano H; Kitamura K; Sakamoto Y; Fujita K; Isobe H; Tsujimura A; Muto S; Horie S
    Sci Rep; 2023 May; 13(1):8704. PubMed ID: 37248346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Age, Gleason Score, and PSA are important prognostic factors for survival in metastatic castration-resistant prostate cancer. Results of The Uroncor Group (Uro-Oncological Tumors) of the Spanish Society of Radiation Oncology (SEOR).
    Valero J; Peleteiro P; Henríquez I; Conde A; Piquer T; Lozano A; Soler CC; Muñoz J; Illescas A; Jove J; Flores MM; Baquedano J; Diezhandino P; de Celis RP; Pardo EH; Samper P; Villoslada I; Eguiguren M; Millan V
    Clin Transl Oncol; 2020 Aug; 22(8):1378-1389. PubMed ID: 31989474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy.
    Berg KD; Røder MA; Thomsen FB; Vainer B; Gerds TA; Brasso K; Iversen P
    Prostate; 2015 Oct; 75(14):1499-509. PubMed ID: 26053696
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.
    Hanyok BT; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Posadas EM; Freedland SJ
    Cancer; 2016 Jan; 122(2):222-9. PubMed ID: 26484853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biopsy-detected Gleason grade 5 tumor is an additional prognostic factor in metastatic hormone-sensitive prostate cancer.
    Lim B; Lee W; Kyung YS; You D; Jeong IG; Hong JH; Ahn H; Kim CS
    J Cancer Res Clin Oncol; 2022 Mar; 148(3):727-734. PubMed ID: 33948720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer.
    Dennis ER; Jia X; Mezheritskiy IS; Stephenson RD; Schoder H; Fox JJ; Heller G; Scher HI; Larson SM; Morris MJ
    J Clin Oncol; 2012 Feb; 30(5):519-24. PubMed ID: 22231045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Periprostatic Fat Thickness on MRI is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Chinese Patients With Newly Diagnosed Prostate Cancer Treated With Androgen Deprivation Therapy.
    Huang H; Chen S; Li W; Bai P; Wu X; Xing J
    Clin Genitourin Cancer; 2019 Oct; 17(5):e1036-e1047. PubMed ID: 31281063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intermittent Versus Continuous Androgen Deprivation Therapy for Biochemical Progression After Primary Therapy in Hormone-Sensitive Nonmetastatic Prostate Cancer: Comparative Analysis in Terms of CRPC-M0 Progression.
    Salciccia S; Frisenda M; Tufano A; Di Pierro G; Bevilacqua G; Rosati D; Gobbi L; Basile G; Moriconi M; Mariotti G; Forte F; Carbone A; Pastore A; Cattarino S; Sciarra A; Gentilucci A
    Clin Genitourin Cancer; 2024 Apr; 22(2):74-83. PubMed ID: 37758559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer.
    Moreira DM; Howard LE; Sourbeer KN; Amarasekara HS; Chow LC; Cockrell DC; Hanyok BT; Pratson CL; Aronson WJ; Kane CJ; Terris MK; Amling CL; Cooperberg MR; Liede A; Freedland SJ
    Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):333-7. PubMed ID: 26171882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors for response to intermittent androgen deprivation (IAD) in prostate cancer cases with biochemical progression after surgery.
    Sciarra A; Cattarino S; Gentilucci A; Alfarone A; Innocenzi M; Gentile V; Salciccia S
    Urol Oncol; 2013 Jul; 31(5):607-14. PubMed ID: 21665494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy.
    Lv W; Shang H; Pei X; Chen Y; Xie H; He D; Wang X; Li L
    Int Urol Nephrol; 2017 Jan; 49(1):61-67. PubMed ID: 27837416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate-risk localised prostate cancer - results from a large contemporaneous cohort.
    KandaSwamy GV; Bennett A; Narahari K; Hughes O; Rees J; Kynaston H
    BJU Int; 2017 Nov; 120(5B):E59-E63. PubMed ID: 28317247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database.
    Whitney CA; Howard LE; Posadas EM; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
    Eur Urol Focus; 2017 Oct; 3(4-5):480-486. PubMed ID: 28753787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective study to evaluate the intra-individual reproducibility of bone scans for quantitative assessment in patients with metastatic prostate cancer.
    Reza M; Kaboteh R; Sadik M; Bjartell A; Wollmer P; Trägårdh E
    BMC Med Imaging; 2018 May; 18(1):8. PubMed ID: 29728144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of bone scan index in the prognosis and effects of therapy on prostate cancer with bone metastasis: Study design and rationale for the multicenter Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index (PROSTAT-BSI) study.
    Nakajima K; Kaneko G; Takahashi S; Matsuyama H; Shiina H; Ichikawa T; Horikoshi H; Hashine K; Sugiyama Y; Miyao T; Kamiyama M; Harada K; Ito A; Mizokami A;
    Int J Urol; 2018 May; 25(5):492-499. PubMed ID: 29633398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index.
    Ulmert D; Kaboteh R; Fox JJ; Savage C; Evans MJ; Lilja H; Abrahamsson PA; Björk T; Gerdtsson A; Bjartell A; Gjertsson P; Höglund P; Lomsky M; Ohlsson M; Richter J; Sadik M; Morris MJ; Scher HI; Sjöstrand K; Yu A; Suurküla M; Edenbrandt L; Larson SM
    Eur Urol; 2012 Jul; 62(1):78-84. PubMed ID: 22306323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.